Ivosidenib API

CAS 1448347-49-6

General Information

Ivosidenib, sold under the brand name Tibsovo, is used in adults whose cancer is newly diagnosed and who are either 75 years and older or cannot be treated with other anticancer drugs. Ivosidenib blocks the protein made by the mutated IDH1 gene. Blocking this protein may help keep cancer cells from growing. Ivosidenib is a type of enzyme inhibitor and a type of targeted therapy for patients diagnosed with Glioma, Acute Myeloid Leukemia (AML), Cholangiocarcinoma, and Chondrosarcoma.

Ivosidenib is the first and only approved drug indicated for the treatment of relapsed or refractory acute myeloid leukemia in adults with an isocitrate dehydrogenase-1 mutation.

It’s expected to become the standard of care for this condition, and received FDA priority review based on impressive clinical results.

We are offering you our own novel stable crystalline form T11 of the Ivosidenib API. It has a complex synthesis which allows for full control of the configuration of the stereocenters, producing an API with high optical purity. With a fully back-integrated process, you know you’re in good hands.

Contact us today for GMP samples! The GMP material is for development or registration purposes only.

About the API

Systematic name (2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
Trade name(s) Tibsovo
Technology Synthetic
Molecular Formula C28H22ClF3N6O3
Molecular Weight 582.97 g/mol
Therapeutic category Oncology
Available formulations Oral Solid